Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gliadel Wafer plus temozolomide with radiotherapy in primary glioblastoma
2008-003905-15Phase 2Active
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Jul 2008
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carmustine and temozolomide in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Carlo Besta Neurological Institute. Primary endpoint: % progression-free survival at 12 months (%PFS-12). Started Jul 2008; status: active.
02
Drugs
carmustinetemozolomide
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on 2008-003905-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003905-15.